Врожденная инфантильная фибросаркома мягких тканей грудной стенки слева (описание клинического случая и обзор литературы)

Инфантильная фибросаркома (ИФ) – редкая саркома мягких тканей, возникающая с частотой 1 % всех случаев злокачественных новообразований у детей на первом году жизни. ИФ чаще всего поражает мягкие ткани верхних и нижних конечностей. К редким локализациям относят туловище, область головы и шеи и желудочно-кишечный тракт. В статье описан редкий клинический случай врожденной ИФ мягких тканей грудной стенки у новорожденного, а также литературный обзор.

1. Kaatsch P., Spix C. German Childhood Cancer Registry – Annual Report 2015 (1980–2014). Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), at the University Medical Center of the Johannes Gutenberg University Mainz, 2015.

2. Cecchetto G., Carli M., Alaggio R., Dall’Igna P., Bisogno G., Scarzello G., Zanetti I., Durante G., Inserra A., Siracusa F., Guglielmi M.; Italian Cooperative Group. Fibrosarcoma in pediatric patients: results of the Italian cooperative group studies (1979–1995). J Surg Oncol 2001;78:225–31. doi: 10.1002/jso.1157.

3. Coffin C.M., Dehner L.P. Soft tissue tumors in first year of life: a report of 190 cases. Pediatr Pathol 1990;10:509–26. doi: 10.3109/15513819009067140.

4. Zeytun H., Okur M.H., Basuguy E., Arslan S., Aydogdu B., Turkcu G., Arslan M.S. Congenital-infantile fibrosarcoma of the ileocecal region: the first case presentation. Pediatr Surg Int 2016;32(1):97–9. doi: 10.1007/s00383-015-3802-0.

5. Gurney J.G., Young J.L., Roffers S.D., Smith M.A., Bunin G.R. Soft tissue sarcomas. In: Gloecker Ries I.A., Smith M.A., Gurney J.G., Linet M., Tamra T., Young J.L., Bunin G.R., eds. SEER pediatric monograph: cancer incidence and survival among children and adolescents, United States SEER program 1975–1995. National Cancer Institute, Bethesda, 1999. Pp. 111–124.

6. Parida L., Fernandez-Pineda I., Uffman J.K., Davidoff A.M., Krasin M.J., Pappo A., Rao B.N. Clinical management of infantile fibrosarcoma: a retrospective single-institution review. Pediatr Surg Int 2013;29(7):703–8. doi: 10.1007/s00383-013-3326-4.

7. Сагоян Г.Б., Качанов Д.Ю., Курникова М.А., Сулейманова А.М., Большаков Н.А., Рощин В.Ю., Терещенко Г.В., Пшонкин А.В., Шаманская Т.В., Варфоломеева С.Р. Ранняя диагностика мышечной дистрофии Дюшенна у ребенка с врожденной инфантильной фибросаркомой мягких тканей правого плеча. Педиатрия. Журнал им. Г.Н. Сперанского 2019;98(4):275–81. doi: 10.24110/0031-403X-2019-98-4-281.

8. Ferguson W.S. Advances in the adjuvant treatment of infantile fibrosarcoma. Exp Rev Anticancer Ther 2003;3:185–91. doi: 10.1586/14737140.3.2.185.

9. Coffin C.M., Dehner L.P. Fibroblastic-myofibroblastic tumors in children and adolescents clinicopathologic study of 108 examples in 222 patients. Pediatr Pathol 1991;11(4):569–88. doi: 10.3109/15513819109064791.

10. Lagree M., Toutain F., Revillon Y., Gaussin G., Marie-Cardine A., Lemoine F., Vannier J.P. Recurrent and metastatic infantile fibrosarcoma: a case report. Arch Pediatr 2011;18(1):28–32. doi: 10.1016/j.arcped.2010.10.004.

11. Pandey A., Kureel S.N., Bappavad R.P. Chest Wall Infantile Fibrosarcomas – A Rare Presentation. Indian J Surg Oncol 2016;7(1):127–9. doi: 10.1007/s13193-016-0487-3.

12. van Grotel M., Blanco E., Sebire N.J., Slater O., Chowdhury T., Anderson J. Distant metastatic spread of molecularly proven infantile fibrosarcoma of the chest in a 2-month-old girl: case report and review of literature. J Pediatr Hematol Oncol 2014;36(3):231–3. doi: 10.1097/MPH.0000000000000055.

13. Shamberger R.C., Grier H.E., Weinstein H.J., Perez-Atayde A.R., Tarbell N.J. Chest wall tumors in infancy and childhood. Cancer 1989;63(4):774–85. doi: 10.1002/1097-0142(19890215)63:4<774::aid-cncr2820630429>3.0.co;2-2.

14. Sultan I., Casanova M., Al-Jumaily U., Meazza C., Rodriguez-Galindo C., Ferrari A. Soft tissue sarcomas in the first year of life. Eur J Cancer 2010;46(13):2449–56. doi: 10.1016/j.ejca.2010.05.002.

15. Coffin C.M., Fletcher J.A. Infantile fibrosarkoma. In: Fletcher С.D., Unni K.K., Mertens F., eds. WHO classification of tumours. Pathology and Genetics. Tumours of Soft Tissue and Bone. Lyon: IARC Press, 2002. Pp. 98–100.

16. Knezevich S.R., McFadden D.E., Tao W., Lim J.F., Sorensen P.H. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998;18(2):184–7. doi: 10.1038/ng0298-184.

17. Wegert J., Vokuhl C., Collord G., Del Castillo Velasco-Herrera M., Farndon S.J., Guzzo C., Jorgensen M., Anderson J., Slater O., Duncan C., Bausenwein S., Streitenberger H., Ziegler B., Furtwängler R., Graf N., Stratton M.R., Campbell P.J., Jones D.T., Koelsche C., Pfister S.M., Mifsud W., Sebire N., Sparber-Sauer M., Koscielniak E., Rosenwald A., Gessler M., Behjati S. Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nat Commun 2018;9(1):2378. doi: 10.1038/s41467-018-04650-6.

18. Orbach D., Rey A., Ceccheto G., Oberlin O., Casanova M., Thebaud E., Scopinaro M., Bisogno G., Carli M., Ferrari A. Infantile fibrosarcoma: management based on European exrerience. J Clin Oncol 2010;28(2):318–23. doi: 10.1200/JCO.2009.21.9972.

19. Loh M.L., Ahn P., Perez-Atayde A.R., Gebhardt M.C., Shamberger R.C., Grier H.E. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children’s Hospital, Boston. J Pediatr Hematol Oncol 2002;24(9):722–6. doi: 10.1097/00043426-200212000-00008.

20. Orbach D., Brennan B., De Paoli A., Gallego S., Mudry P., Francotte N., van Noesel M., Kelsey A., Alaggio R., Ranchère D., De Salvo G.L., Casanova M., Bergeron C., Merks J.H., Jenney M., Stevens M.C., Bisogno G., Ferrari A. Conservative strategy in infantile fibrosarcoma is possible: the European Paediatric Soft Tissue Sarcoma Study Group experience. Eur J Cancer 2016;57:1–9. doi: 10.1016/j.ejca.2015.12.028.

21. Sulkowski J.P., Raval M.V., Browne M. Margin status and multimodal therapy in infantile fibrosarcoma. Pediatr Surg Int 2013;8(29):771–6. doi: 10.1007/s00383-013-3318-4.

22. Minard-Colin V., Orbach D., Martelli H., Bodemer C., Oberlin O. Soft tissuetumors in neonates. Arch Pediatr 2009;16(7):1039–48. doi: 10.1016/j.arcped.2009.03.005.

23. Hyman D.M., Taylor B.S., Baselga J. Implementing genomic-driven oncology. Cell 2017;168(2):584–99. doi: 10.1016/j.cell.2016.12.015.

24. Garber K. In a maior shift, cancer drugs go “tissue-agnostic”. Science 2017;356(6343):1111–2. doi: 10.1126/science.356.6343.1111.

25. Laetsch T.W., DuBois S.G., Mascarenhas L., Turpin B., Federman N., Albert C.M., Nagasubramanian R., Davis J.L., Rudzinski E., Feraco A.M., Tuch B.B., Ebata K.T., Reynolds M., Smith S., Cruickshank S., Cox M.C., Pappo A.S., Hawkins D.S. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 2018;19(5):705–14. doi: 10.1016/S1470-2045(18)30119-0.

26. Drilon A., Laetsch T.W., Kummar S., DuBois S.G., Lassen U.N., Demetri G.D., Nathenson M., Doebele R.C., Farago A.F., Pappo A.S., Turpin B., Dowlati A., Brose M.S., Mascarenhas L., Federman N., Berlin J., El-Deiry W.S., Baik C., Deeken J., Boni V., Nagasubramanian R., Taylor M., Rudzinski E.R., Meric-Bernstam F., Sohal D.P.S., Ma P.C., Raez L.E., Hechtman J.F., Benayed R., Ladanyi M., Tuch B.B., Ebata K., Cruickshank S., Ku N.C., Cox M.C., Hawkins D.S., Hong D.S., Hyman D.M. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018;378(8):731–9. doi: 10.1056/NEJMoa1714448.

27. Berger S., Nartens U.M., Bochum S. Larotrectinib (LOXO-101). Rec Res Cancer Res 2018;211:141–51. doi: 10.1007/978-3-319-91442-8_10.